« INDUSTRY NEWS
Academy of Sciences, has received an Agilent Thought Leader award in recognition of her scientifi c contributions to cellular biology and the understanding of neurodegenerative diseases.
Dr. Yuan heads the Chinese Academy of Science’s newly established Interdisciplinary Research Center on Biology and Chemistry. She plans to use Agilent’s integrated biology technologies to expand her metabolomics-based approach for studying neurodegenerative diseases and gain deeper insights into neurodegenerative processes.
“Integrating our metabolomics data with transcriptomic and proteomic data will allow us to better study disease pathogenesis by more fully understanding underlying disease biology,” said Dr. Yuan. “Our aim is to identify five to 10 protein targets or biomarkers for neurodegenerative diseases within the next three years.”
Dr. Yuan and her team, headed by mass spectrometry specialist Dr. Zhengjiang Zhu, seek important insights into the complex interactions of metabolite-protein, protein-protein and genetic networks involved in the etiology of neurodegenerative disease. They will use Agilent’s metabolomics workflows and integrated biology software solutions, 6400 Series Triple Quadrupole LC/MS system, and GeneSpring software in their work.
Dr. Yuan’s research has uncovered many signifi cant distinctions in the multiple cell death mechanisms, including programmed cell death (apoptosis) and necroptosis elicited by external factors such as infection, toxins or trauma (necrosis). Her recent work focuses on the identifi cation of necrostatins, a family of small molecule inhibitors of necroptosis, which is a regulated necrotic cell death mechanism.
Royal DSM and JLL Create Leading Pharma Services Company in USD 2.6B Transaction
JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, announced the creation of a new company, which will be a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of around USD 2 billion. It will be 51% owned by JLL and 49% by DSM.
The name of the company (provisionally called NewCo) will be announced in the coming months. NewCo will be formed by combining DSM’s business group DSM Pharmaceutical Products (“DPP”) with Patheon Inc. (“Patheon”), after a successful completion of the transaction. NewCo will be a leading global contract development and manufacturing organization with anticipated 2014 sales of about USD 2 billion (pro-forma) and a strong EBITDA and operational cash flow.
NewCo will have an end-to-end offering from finished dosage (drug products) to active substances (APIs) and a global footprint of 23 locations across North America, Europe, Latin America and Australia with about 8,300 employees.
Combining DPP and Patheon is fully in line with DSM’s strategy for its Pharma cluster as well as an excellent value creation opportunity as DSM and JLL will work together to maximize the value of NewCo. For DSM, combining DPP with Patheon into NewCo is also a key step in the strategic transformation of its Pharma activities into partnerships.
Once the transaction is complete, NewCo will add scale and new value chain capabilities/technologies to expand its end-to-end service off ering as a comprehensive solution provider to the industry. NewCo will operate as an independent standalone company.
NewCo will have a unique breadth of service offerings with a focus on drug products and APIs with a wide range of technologies and will be able to offer comprehensive end-to-end solutions to a broad spectrum of companies ranging from large pharmaceutical and biotech companies to specialty pharma companies, generics and emerging pharma companies.
The combined company will also be a leader in proprietary softgel formulations for over-the-counter, prescription and nutritional consumer products.
The exclusive synthesis products and
intermediates are targeted to the crop protection, personal care, and fine chemicals products industries.
Jim Mullen, currently CEO of Patheon, will be appointed CEO of NewCo upon completion of the transaction.
Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market
BD AccelerateSM Program Designed to Bring Pharmaceutical Customers’ Drugs to Market Faster
BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that the BD AccelerateSM program now offers a solution for the biopharmaceutical injectable drug market with the BD Neopak™ Glass Prefillable Syringe system. This make-to-stock program is designed to facilitate expedited delivery, within two weeks, of fully-validated BD syringe systems and associated quality systems documentation to pharmaceutical customers.
Launched in 2011, the program was designed to off er pharmaceutical customers faster access to fully-validated syringe systems that are optimized for biologics, vaccines and other parenteral medicines. Based on BD’s high-speed manufacturing capabilities, the BD AccelerateSM program allows the company to produce and store large quantities of fully-validated syringe components. This program represents a signifi cant reduction in lead time versus traditional processes and provides customers with the advantage to initiate testing earlier in the drug development process.
“By offering faster access to a syringe system that is specifically engineered for the delivery of biopharmaceutical drugs, BD is positioned to provide an important advantage to companies
www.americanpharmaceuticalreview.com | | 81
»
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92